


# Chloroquine and hydroxychloroquine experience significant price increase due to corona virus crisis

Shortly after the outbreak of the corona crisis, scientists started to test existing drugs as potential remedies. Two malaria drugs – Chloroquine **CQ** and Hydroxychloroquine **HCQ** – received particular attention and widespread media coverage. The resulting demand increase sent prices for the active pharmaceutical ingredients (APIs) soaring in the first quarter of 2020.




## Key takeaways

Compared to other drugs, **CQ** and **HCQ** have shown fairly stable prices over the last quarter of 2019 (Q4/19)

In the same time frame, **CQ** has seen an even sharper increase (+230%) from about 28 USD/kg to more than 92 USD/kg

In Q1 of 2020, prices for **HCQ** have increased by about 90% from about 155 USD/kg at the beginning of January to more than 295 USD/kg by the end of March



## Sources:

QYOBO platform - global average API price; international trade statistics.

## About QYOBO:

QYOBO GmbH is a Munich-based tech company providing actionable market insights on the API, excipient and chemical markets. The company has developed proprietary big data algorithms to process and enrich data from a large variety of distributed data sources. Leveraging this expertise, QYOBO provides its clients with a one-stop solution to benchmark prices, analyze trends, identify relevant trading partners and streamline adjacent sales and procurement workflows.

## Disclaimer:

The information in this article is not intended to be used for medication purposes. It is explicitly stated, that the above substances are still UNDER EVALUATION and have not yet been formally approved by the relevant regulatory authorities (e.g. WHO, EMA, FDA) for treatment of CoViD-19. Please do not self-medicate and consult a physician/doctor for any questions with regard to your personal medical needs. This assessment has been prepared adhering to the highest quality standards based on a variety of external data sources (see sources) with the purpose of making distributed information accessible to a broader audience. The information contained in this document is provided on an "as is" basis and QYOBO GmbH assumes no responsibility or liability for the completeness, accuracy, usefulness or timeliness of the information provided.